Could a common heart drug help kids on dialysis fight anemia?

NCT ID NCT07715318

Not yet recruiting Disease control Sponsor: Ain Shams University Source: ClinicalTrials.gov ↗

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether spironolactone, a drug usually used for heart failure and high blood pressure, can help treat anemia in children aged 6–18 who are on hemodialysis. Participants take spironolactone daily for 12 weeks alongside standard care, and researchers measure whether it reduces the dose of erythropoietin needed to manage their anemia. The study also monitors safety, especially potassium levels, in this vulnerable group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: spironolactone
What this could lead to: If it works, this could offer a new way to manage anemia in children on dialysis, potentially reducing their need for erythropoietin injections.
What could go wrong: This is a small, early-phase trial with only 40 participants, so results may not apply broadly. Spironolactone can raise potassium levels, which is a risk in kidney patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anemia chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANEMIA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.